康缘药业: 江苏康缘药业股份有限公司关于公司控股股东因公司回购注销限制性股票持股比例被动增加触及1%整数倍的公告

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. completed the repurchase and cancellation of restricted stocks, resulting in a passive increase in the shareholding ratio of its controlling shareholder, Kangyuan Group, from 30.94% to 31.12% [1][2][3] Summary by Sections 1. Completion of Restricted Stock Repurchase - The company repurchased and canceled a total of 3,300,300 restricted stocks, reducing the total share capital from 569,459,106 shares to 566,158,806 shares [2] - The repurchase and cancellation were confirmed by China Securities Depository and Clearing Corporation Limited Shanghai Branch on May 29, 2025 [2] 2. Changes in Shareholding Ratios - Following the repurchase, Kangyuan Group's shareholding ratio increased from 30.94% to 31.12%, while the number of shares held remained unchanged at 176,173,467 shares [2] - Other shareholders, including Yin Ye Gong Yu No. 10 Private Securities Investment Fund, Mr. Xiao Wei, and Nanjing Kangzhu Enterprise Management Partnership, did not experience changes in their shareholding quantities [2] 3. Regulatory Compliance - The company will proceed with the necessary business registration changes following the completion of the stock repurchase and cancellation [2] - The announcement serves as a compliance measure for changes in shareholding ratios that touch upon 1% integer multiples [3]